Toward a safer integration profile of MLV-based retroviral vectors

Molecular Therapy

Volumn 22, Issue 8, 2014, Pages 1405-1406

  Schambach, Axel ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBX1 PROTEIN; HYBRID PROTEIN; INTEGRASE; LENS EPITHELIUM DERIVED GROWTH FACTOR; MURINE LEUKEMIA VIRUS INTEGRASE; PEPTIDES AND PROTEINS; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; LENTIVIRUS VECTOR; MURINE LEUKEMIA VIRUS VECTOR;

CARBOXY TERMINAL SEQUENCE; ENHANCER REGION; EVI1 GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE STRUCTURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMOLOGOUS RECOMBINATION; HUMAN; LMO2 GENE; LONG TERMINAL REPEAT; MDS GENE; MURINE LEUKEMIA VIRUS; NONHUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE; PROGENITOR CELL LINE; PROMOTER REGION; PROTEIN DEGRADATION; PROTO ONCOGENE; VIRAL GENE THERAPY; VIRUS DNA CELL DNA INTERACTION; CHROMATIN; CPG ISLAND; HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION INITIATION SITE;

EID: 84905385285     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.124     Document Type: Note

References (20)

1. Aiuti, A, Cattaneo, F, Galimberti, S, Benninghoff, U, Cassani, B, Callegaro, L et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360: 447-458.
2. Hacein-Bey-Abina, S, Le Deist, F, Carlier, F, Bouneaud, C, Hue, C, De Villartay, JP et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185-1193.
3. Gaspar, HB, Parsley, KL, Howe, S, King, D, Gilmour, KC, Sinclair, J et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187.
4. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
5. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
6. Stein, S, Ott, MG, Schultze-Strasser, S, Jauch, A, Burwinkel, B, Kinner, A et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16: 198-204.
7. Sadelain, M, Papapetrou, EP and Bushman, FD (2012). Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer 12: 51-58.
8. El Ashkar, S et al. (2014). BET-independent MLV-based vectors target away from promoters and regulatory elements. Mol Ther Nucleic Acids (2014) 3, e179; doi:10. 1038/mtna. 2014. 33. Published online 29 July 2014.
9. Derse, D, Crise, B, Li, Y, Princler, G, Lum, N, Stewart, C et al. (2007). Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses. J Virol 81: 6731-6741.
10. Mitchell, RS, Beitzel, BF, Schroder, AR, Shinn, P, Chen, H, Berry, CC et al. (2004). Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2: E234.
11. De Rijck, J, de Kogel, C, Demeulemeester, J, Vets, S, El Ashkar, S, Malani, N et al. (2013). The BET family of proteins targets moloney murine leukemia virus integration near transcription start sites. Cell Rep 5: 886-894.
12. Sharma, A, Larue, RC, Plumb, MR, Malani, N, Male, F, Slaughter, A et al. (2013). BET proteins promote efficient murine leukemia virus integration at transcription start sites. Proc Natl Acad Sci USA 110: 12036-12041.
13. Gupta, SS, Maetzig, T, Maertens, GN, Sharif, A, Rothe, M, Weidner-Glunde, M et al. (2013). Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration. J Virol 87: 12721-12736.
14. Meehan, AM and Poeschla, EM (2010). Chromatin tethering and retroviral integration: recent discoveries and parallels with DNA viruses. Biochim Biophys Acta 1799: 182-191.
15. Christ, F and Debyser, Z (2013). The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy. Virology 435: 102-109.
16. Ciuffi, A and Bushman, FD (2006). Retroviral DNA integration: HIV and the role of LEDGF/p75. Trends Genet 22: 388-395.
17. Gijsbers, R, Ronen, K, Vets, S, Malani, N, De Rijck, J, McNeely, M et al. (2010). LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol Ther 18: 552-560.
18. Vets, S, De Rijck, J, Brendel, C, Grez, M, Bushman, F, Debyser, Z et al. (2013). Transient expression of an LEDGF/p75 chimera retargets lentivector integration and functionally rescues in a model for X-CGD. Mol Ther Nucleic Acids 2: e77.
19. Genovese, P, Schiroli, G, Escobar, G, Di Tomaso, T, Firrito, C, Calabria, A et al. (2014). Targeted genome editing in human repopulating haematopoietic stem cells. Nature 510: 235-240.
20. Aiyer, S, Swapna, GV, Malani, N, Aramini, JM, Schneider, WM, Plumb, MR et al. (2014). Altering murine leukemia virus integration through disruption of the integrase and BET protein family interaction. Nucleic Acids Res 42: 5917-5928.